BAJAJ BROKING

Notification close image
No new Notification messages
card image
JSW Cement Ltd IPO is Open!
Apply for the JSW Cement Ltd IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Biocon Q1 Results FY25-26: Net Profit at ₹31 Cr; Revenue Rises 15% YoY to ₹3,942 Cr

Biocon Q1 Results FY25-26: Net Profit at ₹31 Cr; Revenue Rises 15% YoY to ₹3,942 Cr

Quick Insights

  • Operating revenue stood at ₹3,942 crore in Q1 FY26, marking a 15% YoY increase.

  • Net profit came in at ₹31 crore, compared to ₹648 crore (ex-BFI gain) last year.

  • EBITDA rose 19% YoY (like-for-like) to ₹829 crore, with a margin of 21%.

  • Core EBITDA was ₹1,003 crore, representing 25% margin.

  • Biosimilars segment led growth, up 18% YoY, followed by CRDMO at 11% and Generics at 6%.

Quarterly – Biocon Q1 Results FY25-26

Particulars

Q1 FY26 (₹ Cr)

Q1 FY25 (₹ Cr)

YoY (%)

Generics

697

659

6%

Biosimilars

2,458

2,083

18%

CRDMO (Syngene)

875

790

11%

Inter-segment Revenue

(87)

(99)

-13%

Revenue from Operations

3,942

3,433

15%

Other Income

80

1,134*

-93%

Total Revenue

4,022

4,567

-12%

Net R&D Expenses

205

228

-10%

EBITDA

829

1,755*

-53%

EBITDA Margin

21%

38%

Core EBITDA

1,003

903

11%

Core EBITDA Margin

25%

26%

PBT (Before Exceptional Items)

97

1,114*

-91%

Net Profit (Before Exceptional Items)

31

648*

-95%

Net Profit (Reported)

31

660

-95%

*Q1 FY25 includes a one-time BFI divestment gain of ₹1,057 crore.

   

BIOCON LIMITED.

Trade

349.6-14.60 (-4.00 %)

Updated - 08 August 2025
365.80day high
DAY HIGH
349.00day low
DAY LOW
2148156
VOLUME (BSE)

Segment Highlights

  • Generics revenue stood at ₹697 crore (+6% YoY), driven by launches like Liraglutide in the EU, Dasatinib and Lenalidomide in the U.S., and higher API volumes.

  • Biosimilars posted ₹2,458 crore (+18% YoY) with strong launches including Yesafili™ in Canada and FDA approval for Kirsty™ (Insulin Aspart) in the U.S.

  • CRDMO (Syngene) revenue reached ₹875 crore (+11% YoY), aided by long-term contract conversions and new capability additions in biologics manufacturing.

Sector Expectations for Biocon Q1 Results FY25-26

The 15% YoY growth in operating revenue aligned with market expectations, though net profit declined due to the absence of last year’s exceptional BFI gain. Margin expansion in the biosimilars segment and new product approvals position Biocon for sustained growth in FY26. The CRDMO division’s steady performance and strategic capacity expansions further strengthen long-term prospects.

Management Commentary

Commenting on the quarterly results, Kiran Mazumdar-Shaw, Chairperson of Biocon Group said, “Biocon opened FY26 with a strong performance, driven by continued gains in Biosimilars and CRDMO, and a steady showing in Generics. Operating Revenue rose 15% YoY to Rs 3,942 crore, with EBITDA up 19% on a like-for-like basis, demonstrating operating leverage and the robustness of our businesses. The recent QIP has strengthened our balance sheet and enables us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities. Key developments this quarter include the launch of Yesafili™ in Canada, our tenth biosimilar globally, and USFDA approval for Insulin Aspart, our second interchangeable biosimilar Insulin, further deepening our presence in the U.S. insulin market. With execution momentum across all businesses and expanded capacity through acquisitions in the U.S. by Syngene and Biocon Generics, we are well-positioned to drive long-term value creation in FY26 and beyond.”

Source: Q1 FY25-26 Quarterly Results uploaded on 7th August, 2025, on BSE.

For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|